125 related articles for article (PubMed ID: 723476)
1. Allantoxanamide: a potent new uricase inhibitor in vivo.
Johnson WJ; Chartrand A
Life Sci; 1978 Nov; 23(22):2239-44. PubMed ID: 723476
[No Abstract] [Full Text] [Related]
2. Uricostatic effect of allopurinol in the allantoxanamide-treated rat: a new method for evaluating antiuricopathic drugs.
Hropot M; Muschaweck R; Klaus E
Adv Exp Med Biol; 1984; 165 Pt A():175-8. PubMed ID: 6720375
[No Abstract] [Full Text] [Related]
3. Hyperuricemia and locomotor activity in developing rats.
Barrera CM; Hunter RE; Dunlap WP
Pharmacol Biochem Behav; 1989 Jun; 33(2):367-9. PubMed ID: 2813475
[TBL] [Abstract][Full Text] [Related]
4. Allantoxanamide-induced myocardial necrosis in Sprague-Dawley vs spontaneously hypertensive rats.
Wexler BC
Proc Soc Exp Biol Med; 1982 Sep; 170(4):476-85. PubMed ID: 7122477
[No Abstract] [Full Text] [Related]
5. Effect of fructose administration on serum urate levels in the uricase inhibited rat.
Stavric B; Johnson WJ; Clayman S; Gadd RE; Chartrand A
Experientia; 1976 Mar; 32(3):373-4. PubMed ID: 1253916
[No Abstract] [Full Text] [Related]
6. Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings].
Winocour PD; Munday KA; Taylor TG; Tuner MR
Proc Nutr Soc; 1976 Sep; 35(2):54A-55A. PubMed ID: 972878
[No Abstract] [Full Text] [Related]
7. Uricase inhibition in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria.
Johnson WJ; Stavric B; Chartrand A
Proc Soc Exp Biol Med; 1969 May; 131(1):8-12. PubMed ID: 5770131
[No Abstract] [Full Text] [Related]
8. Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B; Nera EA
Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
[TBL] [Abstract][Full Text] [Related]
9. Decreasing effect of allantoxanamide, a hyperuricemic agent on renal functions in rats.
Yonetani Y; Iwaki K; Ogawa Y
Jpn J Pharmacol; 1987 Sep; 45(1):37-43. PubMed ID: 3119902
[TBL] [Abstract][Full Text] [Related]
10. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.
Chaudhary A; He Z; Atwood DJ; Miyazaki M; Oto OA; Davidoff A; Edelstein CL
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1004-F1015. PubMed ID: 38634129
[TBL] [Abstract][Full Text] [Related]
11. Sites of urate transport in the rat nephron.
Greger R; Lang F; Deetjen P; Knox FG
Adv Exp Med Biol; 1977; 76B():90-9. PubMed ID: 855767
[No Abstract] [Full Text] [Related]
12. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor.
Stavric B; Nera EA; Johnson WJ; Salem FA
Invest Urol; 1973 Jul; 11(1):3-8. PubMed ID: 4724271
[No Abstract] [Full Text] [Related]
13. Pharmacological effects of 1,3,5-triazines and their excretion characteristics in the rat.
Hropot M; Sörgel F; von Kerékjártó B; Lang HJ; Muschaweck R
Adv Exp Med Biol; 1980; 122A():269-76. PubMed ID: 6893515
[No Abstract] [Full Text] [Related]
14. Uric acid nephropathy in shocked rats after blocking of uricase activity with triazine compounds.
Boda D; Pénzes P; Gecse A; Streitman K; Zsilinszky E; Karády I
Can J Physiol Pharmacol; 1973 Jun; 51(6):496-8. PubMed ID: 4727817
[No Abstract] [Full Text] [Related]
15. Low uricase activity in the Dalmatian dog simulated in mongrels given oxonic acid.
Yü TF; Gutman AB; Berger L; Kaung C
Am J Physiol; 1971 Apr; 220(4):973-9. PubMed ID: 5551153
[No Abstract] [Full Text] [Related]
16. Potent competitive uricase inhibitors--2,8-diazahypoxanthine and related compounds.
Iwata H; Yamamoto I; Goda E; Morita K; Nakamura M
Biochem Pharmacol; 1973 Sep; 22(18):2237-45. PubMed ID: 4733677
[No Abstract] [Full Text] [Related]
17. Diet-induced hyperuricaemia and platelet aggregation in rats.
Winocour PD; Munday KA; Taylor TG; Turner MR
Proc Nutr Soc; 1977 Sep; 36(2):86A. PubMed ID: 905317
[No Abstract] [Full Text] [Related]
18. A preliminary report of nephropathy in hyperuricemic rats.
Waisman J; Bluestone R; Klinenberg JR
Lab Invest; 1974 Jun; 30(6):716-22. PubMed ID: 4835598
[No Abstract] [Full Text] [Related]
19. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
Ishibuchi S; Morimoto H; Oe T; Ikebe T; Inoue H; Fukunari A; Kamezawa M; Yamada I; Naka Y
Bioorg Med Chem Lett; 2001 Apr; 11(7):879-82. PubMed ID: 11294382
[TBL] [Abstract][Full Text] [Related]
20. Diurnal variation in serum uric acid of rats fed potassium oxonate.
Newburger J; Combs AB; Hsu TF
Drug Chem Toxicol; 1978; 1(3):231-5. PubMed ID: 573681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
